It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite known histological, biological, and clinical differences between lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), relatively little is known about the spatial differences in their corresponding immune contextures. Our study of over 1000 LUAD and LUSC tumors revealed that computationally derived patterns of tumor-infiltrating lymphocytes (TILs) on H&E images were different between LUAD (N = 421) and LUSC (N = 438), with TIL density being prognostic of overall survival in LUAD and spatial arrangement being more prognostically relevant in LUSC. In addition, the LUAD-specific TIL signature was associated with OS in an external validation set of 100 NSCLC treated with more than six different neoadjuvant chemotherapy regimens, and predictive of response to therapy in the clinical trial CA209-057 (n = 303). In LUAD, the prognostic TIL signature was primarily comprised of CD4+ T and CD8+ T cells, whereas in LUSC, the immune patterns were comprised of CD4+ T, CD8+ T, and CD20+ B cells. In both subtypes, prognostic TIL features were associated with transcriptomics-derived immune scores and biological pathways implicated in immune recognition, response, and evasion. Our results suggest the need for histologic subtype-specific TIL-based models for stratifying survival risk and predicting response to therapy. Our findings suggest that predictive models for response to therapy will need to account for the unique morphologic and molecular immune patterns as a function of histologic subtype of NSCLC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Case Western Reserve University, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847)
2 Stony Brook University, New York, USA (GRID:grid.36425.36) (ISNI:0000 0001 2216 9681)
3 Case Western Reserve University, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Louis Stokes Cleveland VA Medical Center, Cleveland, USA (GRID:grid.410349.b) (ISNI:0000 0004 5912 6484)
4 University of Bern, Institute of Pathology, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Graduate School for Health Sciences, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
5 Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
6 University of Bern, Institute of Pathology, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); Lausanne University Hospital and University of Lausanne, Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne, Switzerland (GRID:grid.8515.9) (ISNI:0000 0001 0423 4662)
7 Bristol Myers Squibb, New York, USA (GRID:grid.419971.3) (ISNI:0000 0004 0374 8313)
8 Yale University, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
9 New York University, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)